Pay in 4 interest-free payments of $6.13 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
By Application, Type 2 Diabetes Mellitus dominated the GLP-1 Market in 2025
Check labs for ferritin, TSH, vitamin D, B12, and basic metabolic markers before or soon after starting therapy
Retatrutide works as a triple receptor agonist, targeting three key hormonal pathways simultaneously: [1] [4] GLP-1 (glucagon-like peptide-1): Is thought to reduce appetite and slow gastric emptying GIP (glucose-dependent insulinotropic polypeptide): Is thought to enhance insulin secretion and may influence fat metabolism, though human evidence remains limited Glucagon receptor: Has been observed in early studies to increase energy expenditure and promote fat breakdown, though the clinical significance in humans is still being established This triple-action mechanism distinguishes retatrutide from currently approved dual or single agonists
The treatments today are as ineffective as they will ever be, looking ahead: Weight loss efficacy is increasing from 15% to 20% to 25% to 30% The label is expanding from Diabetes to Obesity to Heart Disease and likely Kidney Disease and Sleep Apnea
